Header
For Healthcare Professionals
Logout
bilogo
Spevigo
bilogo
Spevigo
  • Logout

    Spevigo
    • Home
    • About GPP
    • MOA
    • Efficacy
    • Safety
    • Dosing and Administration
    • Expert Opinion
    • SmPC
    test
     Interior_Pages_Hero

    GPP R.E.E.L.S.
    Expert Insight

    GPP R.E.E.L.S.: Expert Insight by Dr Latha Selvarajah on Spesolimab’s Efficacy in GPP Patients without IL-36RN Mutation

    Document ID: SC-MY-05205 | Author: Boehringer Ingelheim 

    1. Home
    2. GPP R.E.E.L.S.: Expert Insight by Dr Latha Selvarajah on Spesolimab’s Efficacy in GPP Patients without IL-36RN Mutation
    boehringer ingelheim
    spevigo
    • Terms of Use Opens in new tab
    • Data Privacy Opens in new tab
    • Imprint Opens in new tab
    • Accessibility Statement Opens in new tab

    Boehringer Ingelheim (Malaysia) Sdn. Bhd. Company No: 198601000452 (149591-H), Level 23A, Mercu Aspire, No. 3, Jalan Bangsar, KL Eco City, 59200 Kuala Lumpur, Tel: +603 2859 3888, Fax: +603 2859 3999

    Copyright © 2023 Boehringer Ingelheim (Malaysia) Sdn Bhd. All rights reserved. Use of this Site is subject to the Terms of Use and Privacy Statement. (06/22) PC-MY-103024
    This website is intended for healthcare professionals in Malaysia. The contents of this website are for information purposes only and are not intended to substitute for advice, treatment or recommendations of a healthcare professional. For your health concerns and other questions about symptoms, treatment or medication, consult a healthcare professional.